Effect of unani formulation on Allergic Rhinitis

Efficacy and safety(ADRs) of habbe nazla(Unani formulation) on patients with allergic rhinitis.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/05/013856

Enrollment

Registered

2018-05-14

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Allergic Rhinitis

Interventions

Intervention1: Habbe-Nazla(Hamdard Waqf Laboratories): Composition of Habbe-Nazla {1.Dalchini(29.92mg)2.Rubb-us-soos(29.92mg)3.Kateera safaid(49.87mg)4.Gond keekar(49.87mg)5.Nishashta gandum(49.87mg)6

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with Allergic Rhinitis. 2. Either sex 3. Patients willing to submit consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnency 2. Chronic or intermittent use of steroids 3. Diabetes Mellitus 4. Chronic Renal Failure 5. Hepatic Failure

Design outcomes

Primary

Measure	Time frame
Clinical parameters:Symptomatic investigations:Sneezing,Itching,Congestion,Headache,Eye swelling,Redeyes,Sleep disturbance Laboratory parameters:IgE,Absolute Eosinophil Count,CBC,LFT,KFT Timepoint: Assessments of patients will be made Pre treatment and Post treatment	—

Secondary

Measure	Time frame
Parameters: Nasal smears for eosinophil count,PNS X-rayTimepoint: Assessments of patients will be made Pre treatment and Post treatment	—

Countries

India

Contacts

Public ContactDr Zehra Zaidi

SPER , Jamia hamdard

msharique12345@gmail.com9990919366

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026